JAZZ
Jazz Pharmaceuticals plc
Healthcare • CIK: 0001232524
Loading...
Market Cap
$10.37B
P/E (TTM)
-29.4x
Rev Growth (TTM)
+4.9%
Net Margin (TTM)
-8.3%
FCF Yield (TTM)
2.5%
FCF Margin (TTM)
6.1%
Cash Flow Health
Free Cash Flow7/8 positive
TTM$258M
Q4 '25
$292M-32%
Q3 '25
$429M+466%
FCF Margin
TTM6.1%
Q4 '2524.4%-36%
Sector: 0.0%Above Avg
OCF Margin31.8%
OCF/NI-3.81x
CapEx Coverage1.4x
FCF Yield2.5%
FCF Growth (2Y)-43%
Cash Conversion Cycle
61 days
DSO: 61+DIO: –−DPO: –
Capital Allocation & Returns
Total Shareholder YieldFY
FY0.0%
Div Yield0.0%
+Buyback (FY)1.2%
Insufficient data
Dividend & Payout Metrics
Dividend Yield (TTM)0.0%
Free Cash Flow (TTM)$258.2M
Stock Repurchases (FY)$125.0M
Capital Return / FCF0.0%
Est. Dividends Paid (TTM)$0
Shows how management rewards shareholders
Operational Efficiency & Returns
Return on Invested CapitalTTM
-2.6%
Volatile
-0.1% YoY+14.7%
P25MedianP75
25th pctl (med: 0.0%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
-5.7%
Asset Turnover
0.38x
8Q: 0.36x
Leverage (1+D/E)
2.24x
D/E: 1.24x
DuPont: -4.8% ≈ -2.6% ROIC
Asset & CapEx Efficiency
Fixed Asset Turn
23.00x
8Q:24.25x
+98.6%
Invested Cap Turn
0.49x
8Q:0.44x
+16.1%
CapEx Intensity
11.3%
8Q:0.6%
CapEx/Depreciation
23.75x
Asset-based ROIC formula
QUARTERLY TRENDS
Last 8 quarters + TTM
| Metric | TTM | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | $4.3B | $1.2B↑6.4% | $1.1B↑7.7% | $1.0B↑16.5% | $897.8M↓17.5% | $1.1B↑3.1% | $1.1B↑3.0% | $1.0B↑13.5% | $902.0M |
Operating Income | $-430.2M | $254.5M↑342.6% | $57.5M↑108.4% | $-686.4M | $0↑100.0% | $-55.9M↓129.3% | $190.8M↓26.7% | $260.2M↑30.5% | $199.4M |
Net Income | $-356.1M | $203.5M↓19.1% | $251.4M↑135.0% | $-718.5M↓676.4% | $-92.5M↓148.4% | $191.1M↓11.1% | $215.1M↑27.6% | $168.6M↑1253.2% | $-14.6M |
Operating Cash Flow | $1.4B | $362.5M↓23.6% | $474.6M↑434.1% | $88.9M↓79.3% | $429.8M↑7.8% | $398.6M↓0.0% | $398.7M↑20.3% | $331.4M↑24.0% | $267.2M |
Free Cash Flow | $258.2M | $292.3M↓31.9% | $429.4M↑465.9% | $75.9M↑108.0% | $-944.2M↓341.5% | $390.9M↑1.5% | $385.3M↓0.7% | $388.0M↑19.6% | $324.3M |
Total Equity | N/A |
Valuation Analysis
Fair Value
Price-to-EarningsTTM
-29.4x
Volatile
8Q: 31.8x+31147%
Valuation Lenses
Earnings
-29.4x
vs – sector
Cash Flow
55.1x
EV/FCF vs –
Growth-Adj
–PEG
N/A
Quality-Adj
–P/E per %ROIC
ROIC: -2.6%
Shareholder Returns
Dividend
–
Buyback
–
Total Yield
–
Market Cap$10.37B
EV$14.23B
Multi-angle valuation analysis with sector context
Business Quality & Moat
Overall Quality Score
-11/100
Below Average
Composite score: Returns (40%) + Consistency (30%) + Earnings Quality (30%)
Returns on Capital
Return on Equity (ROE)Above Avg
-8.9%
8Q:–
Return on Invested Capital (ROIC)Below Avg
-2.6%
8Q:–
+14.7%
DuPont Analysis (ROIC = NOPAT Margin × Asset Turnover)
NOPAT Margin: -5.7%
Asset Turnover: 0.38x
Earnings Quality
Cash Conversion
-3.81x
OCF / Net Income
FCF Consistency
–
Positive quarters
Competitive Moat Indicators
Pricing Power
Gross Margin–
Capital Efficiency
Invested Capital Turnover0.49x
Working Capital
Cash Conversion Cycle61 days
Growth Quality & Momentum
Low Quality
Growth Quality Score
45/100
Growth 40%
Margins 30%
FCF 20%
Consistency 10%
Growth Rates
Revenue Growth YoY
4.9%
OpInc Growth YoY
555.4%
EPS Growth YoY
N/A
FCF 3Y CAGR
-42.6%
Growth Quality Analysis
⚠Working Capital Drag: FCF growth lagging revenue by 47.5%
⚠Sustainability Index: 3.0/10 - Growth sustainability concerns
Margin Quality & Sustainability
Moderate
Profitability Cascade
Gross
—
Operating
-10.1%
Below Avg in sector
Net
-8.3%
Margins Unknown
Earnings Quality Signals
SBC / Revenue
—
FCF vs Net Gap
+14.4 pts
FCF: 6.1% | Net: -8.3%
Quality = stability + cash conversion + low dilution
Balance Sheet & Solvency
Leveraged
Net Debt / EBITDA
–Net Debt: $3.97B
Interest Coverage
–
Leverage Metrics
Debt-to-Equity
1.24x
Balance sheet risk & solvency analysis